2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4211 Risk factors predicting progression to PTLD following EBV reactivation in rabbit ATG-conditioned allo-hematopoeitic stem cell transplant: A multicentre Australian cohort study.

Kirsty Sharplin, MBBS (hons), MSC, Elias Biris, PharmD2, Alia Cibich, BSc3, Matthew Rubic4, David Gottlieb, MD, MBBS, FRACP, FRCPA5, Matthew Greenwood, MBBS, FRACP, FRCPA6, Alice Kwok7, David Ritchie, M.B., Ch.B., Ph.D.8, Ray Mun Koo, MBBS, FRACP, FRCPA9, Duncan Purtill, MBBS FRACP FRCPA10, Marcus Lombard, MBBS11, Andrew Grigg, MD, MBBS, FRACP, FRCPA12, Peter Bardy, FRCP, FRCPath13
1 Oxford University Hospital, Oxford, United Kingdom
2 Royal Adelaide hospital, Adelaide, South Australia, Australia
3 Royal Adelaide hospital, Adelaide, South Australia, Australia
4 Westmead Hospital, Sydney, New South Wales, Australia
5 Westmead Hospital, Sydney, New South Wales, Australia
6 Royal North Shore Hospital, Saint Leonards, New South Wales, Australia, The University of Sydney, Camperdown, New South Wales, Australia
7 Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
8 The Royal Melbourne Hospital, Parkville, Victoria, Australia
9 Fred Hutch Cancer Center, Seattle, Washington, United States
10 Fiona Stanley Hospital, Murdoch, Western Australia, Australia
11 Fiona Stanley Hospital, Murdoch, Western Australia, Australia
12 Austin Hospital, Heidelberg, Victoria, Australia
13 Royal Adelaide hospital, Adelaide, South Australia, Australia

Anti thymocyte globulin (r-ATG), a polyclonal antibody raised in rabbits using human thymocytes, targets a broad array of human T-cell surface molecules. r-ATG decreases the incidence and severity of GVHD. However by depleting donor-derived T-lymphocytes, it impairs cellular immune responses necessary to control certain viral infections, including Epstein-Barr virus (EBV). Reactivation of  (EBVr) can  progress to post transplant lymphoproliferative disorder (PTLD).

As r-ATG clearance is lymphocyte-dependent (Admiraal et al. 2017), profound lymphopenia at the time of administration can significantly delay clearance and impair immune reconstitution and antiviral immunity. Noting that not all patients with EBVr progress to PTLD, we analysed the impact of lymphopenia at the time of r-ATG administration and other variables on the risk of EBVr and PTLD.

METHODS: We retrospectively analysed 803 patients undergoing first allo-HSCT using r-ATG-based GvHD prophylaxis (4.5 mg/kg in divided doses over days -3 to -1) across six Australian transplant centres between 2015-2023. Median follow-up was 4.0 years. EBV monitoring was performed as per local institutional protocol and assay. EBVr was defined by a detectable viral load. PTLD was classified as proven (biopsy-confirmed) or probable (imaging-based). The impact of the following variables for risk of EBVr and PTLD was assessed: lymphopenia (ALC <0.5 x10^9/L) on the day of first ATG dose and day of EBVr, age as a continuous variable, fludarabine conditioning and diagnosis (AML, lymphoma/CLL, MPN, MDS and bone marrow failure). Cumulative incidence functions (CIF) were estimated with death as a competing event. The impact of EBVr and PTLD on overall survival (OS) was assessed by Cox proportional hazards regression with EBVr and PTLD modelled as time-varying covariates, adjusted for age, myeloablative conditioning and diagnosis, and stratified by centre.

RESULTS:. EBVr occurred in 382 patients (1-year 46.6%;95% CI 43.1–50.0%) at median of 46 days post-transplant (IQR 33–60; range 3–1317), Lymphopenia at ATG dosing SHR 1.48 (1.02–2.16), p 0.040),, fludarabine SHR 1.58(1.09–2.28; p 0.015), MDS (SHR 1.66 (1.25–2.22; p <0.001) and bone marrow failure (SHR 2.39 (1.15–4.97;p 0.019 were independently associated with EBVr, while lymphoma/CLL (n=119) was associated with a lower risk SHR 0.70 (0.50–0.98; p 0.037) Among 377 reactivators with complete data, 172 (45.6%) were lymphopenic at time of EBVr.

PTLD occurred in 100 patients PTLD (confirmed n=47, probable n=53) with a 1-year CIF 12.1%, 95% CI 9.9-14.4%); 97 occurred within the first year, all with prior EBVr. Eight deaths were directly attributed to PTLD. The 1-year cumulative incidence of PTLD was 31.4% (95% CI 24.5-38.4%) in lymphopenic patients at the time of EBVr compared with 19.5% (14.1-25.0%) in non-lymphopenic patients. Both lymphopenia at EBVr (SHR 2.02 (1.32–3.09), p 0.001) and prior fludarabine use (SHR 2.07 (1.01–4.26), p 0.048) independently predicted progression of EBVr to PTLD; age. concomitant steroid use, and underlying disease did not.

Lymphopenia at time of r-ATG did not predict lymphopenia at EBVr** (odds ratio 0.59, 95% CI 0.29–1.17, p 0.108; 178 of 316 (56.3%) lymphopenic at r-ATG patients having recovered to at least 0.5 ×10⁹/L by EBVr. It was associated with the development of PTLD (SHR 2.67 (1.14–6.24), p 0.023). 

We assessed a two-factor risk index, assigning one point for lymphopenia at EBVr and fludarabine conditioning and assessed its performance in predicting progression to PTLD. The 1-year PTLD CIF was 9.5% (score 0, n=42), 22.6% (score 1, n=200), and 36.0% (score 2, n=135) (p=0.0002). The index demonstrated modest discrimination 0.60 (bootstrap-corrected, 95% CI 0.55–0.64).

Adjusting for age, conditioning intensity and disease, PTLD was independently associated with an increased risk of death (HR 2.40, 95% CI 1.68–3.44, p<0.001), whereas EBVr was not (HR 1.23, 95% CI 0.92–1.63, p=0.16).

CONCLUSIONS: In r-ATG-conditioned allo-HSCT recipients, lymphopenia at time of r-ATG and use of fludarabine independently impacted on risk of EBVr and lymphopenia at time of EBVr and fludarabine impacted on the risk of PTLD, the latter negatively impacting OS. A simple two factor risk index at the time of EBVr predicts a high risk of subsequent PTLD and may argue for pre-emptive intervention with rituximab in this group.

Kirsty Sharplin, MBBS (hons), MSC: Sanofi - Honoraria; Takeda - Honoraria